DZ2712A1 - Composition de mésylate de trovafloxacine et procédé pour sa préparation. - Google Patents

Composition de mésylate de trovafloxacine et procédé pour sa préparation.

Info

Publication number
DZ2712A1
DZ2712A1 DZ990013A DZ990013A DZ2712A1 DZ 2712 A1 DZ2712 A1 DZ 2712A1 DZ 990013 A DZ990013 A DZ 990013A DZ 990013 A DZ990013 A DZ 990013A DZ 2712 A1 DZ2712 A1 DZ 2712A1
Authority
DZ
Algeria
Prior art keywords
preparation
composition
trovafloxacin mesylate
trovafloxacin
mesylate
Prior art date
Application number
DZ990013A
Other languages
English (en)
French (fr)
Inventor
Altondale Jonhson
Christopher Michael Sinko
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2712A1 publication Critical patent/DZ2712A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ990013A 1998-01-21 1999-01-20 Composition de mésylate de trovafloxacine et procédé pour sa préparation. DZ2712A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7201398P 1998-01-21 1998-01-21

Publications (1)

Publication Number Publication Date
DZ2712A1 true DZ2712A1 (fr) 2003-09-01

Family

ID=22105016

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990013A DZ2712A1 (fr) 1998-01-21 1999-01-20 Composition de mésylate de trovafloxacine et procédé pour sa préparation.

Country Status (34)

Country Link
US (1) US6187341B1 (xx)
EP (1) EP0930068A3 (xx)
JP (1) JPH11269072A (xx)
KR (1) KR100314977B1 (xx)
CN (1) CN1227743A (xx)
AP (1) AP1094A (xx)
AR (1) AR012780A1 (xx)
AU (1) AU758381B2 (xx)
BG (1) BG103106A (xx)
BR (1) BR9900116A (xx)
CA (1) CA2259698C (xx)
CO (1) CO4810225A1 (xx)
DZ (1) DZ2712A1 (xx)
EA (1) EA003247B1 (xx)
GT (1) GT199900004A (xx)
HR (1) HRP990023A2 (xx)
HU (1) HUP9900154A3 (xx)
ID (1) ID23735A (xx)
IL (1) IL128051A0 (xx)
IS (1) IS4947A (xx)
MA (1) MA24747A1 (xx)
NO (1) NO990243L (xx)
NZ (1) NZ333838A (xx)
OA (1) OA10958A (xx)
PA (1) PA8466701A1 (xx)
PE (1) PE20000169A1 (xx)
PL (1) PL330981A1 (xx)
SG (1) SG70666A1 (xx)
SK (1) SK4299A3 (xx)
TN (1) TNSN99007A1 (xx)
TR (1) TR199900089A2 (xx)
TW (1) TW518224B (xx)
YU (1) YU2399A (xx)
ZA (1) ZA99393B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101310T2 (tr) * 1998-11-10 2001-10-22 Bayer Aktiengesellschaft Farmasötik moksifloksasin preparatı.
CA2382834A1 (en) * 1999-09-20 2001-03-29 Alza Corporation Process for lessening polymorphic conversion of a drug
AR025976A1 (es) * 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
FR2808441B1 (fr) * 2000-05-04 2004-06-18 Oreal Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2003088897A2 (en) * 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1396263A1 (en) * 2002-08-09 2004-03-10 Warner-Lambert Company Film coating for tablets and caplets
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
CN100415284C (zh) * 2002-12-30 2008-09-03 毛友昌 六味木香片的制备方法
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
EP1459739B1 (en) * 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CA2531637A1 (en) * 2003-07-23 2005-02-03 L. Perrigo Company Cellulosic fiber containing composition
DK1828167T3 (da) 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
JP5046946B2 (ja) * 2004-10-15 2012-10-10 スパーナス ファーマシューティカルズ インコーポレイテッド 低乱用性薬学的製剤
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ, インク. Fabiインヒビターとしてのアクリルアミド誘導体
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
TR201909016T4 (tr) 2012-06-19 2019-07-22 Debiopharm Int Sa (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri.
AU2017223037B2 (en) 2016-02-26 2022-04-14 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US4957554A (en) 1989-08-16 1990-09-18 Minnesota Mining And Manufacturing Company Dimensionally-controlled ceramics
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
KR100343909B1 (ko) * 1995-08-29 2003-04-10 화이자 인코포레이티드 트로바플록사신의쯔비터이온형태

Also Published As

Publication number Publication date
CO4810225A1 (es) 1999-06-30
TNSN99007A1 (fr) 2005-11-10
NZ333838A (en) 2000-03-27
TR199900089A3 (tr) 1999-10-21
NO990243L (no) 1999-07-22
HUP9900154A2 (hu) 1999-09-28
ID23735A (id) 2000-05-11
AU1217399A (en) 1999-08-12
BR9900116A (pt) 2000-05-02
AP9901443A0 (en) 1999-03-31
PA8466701A1 (es) 2000-09-29
AR012780A1 (es) 2000-11-08
NO990243D0 (no) 1999-01-20
EA199900046A2 (ru) 1999-08-26
SK4299A3 (en) 2000-06-12
KR100314977B1 (ko) 2001-11-24
TR199900089A2 (xx) 1999-10-21
HUP9900154A3 (en) 2000-12-28
OA10958A (en) 2001-10-31
KR19990068014A (ko) 1999-08-25
SG70666A1 (en) 2000-02-22
EP0930068A3 (en) 1999-12-22
IS4947A (is) 1999-07-22
MA24747A1 (fr) 1999-10-01
AP1094A (en) 2002-08-19
PL330981A1 (en) 1999-08-02
BG103106A (en) 1999-08-31
CN1227743A (zh) 1999-09-08
US6187341B1 (en) 2001-02-13
YU2399A (sh) 2002-06-19
EP0930068A2 (en) 1999-07-21
CA2259698C (en) 2003-04-15
HRP990023A2 (en) 1999-08-31
ZA99393B (en) 2000-07-21
CA2259698A1 (en) 1999-07-21
HU9900154D0 (en) 1999-03-29
EA199900046A3 (ru) 1999-12-29
JPH11269072A (ja) 1999-10-05
AU758381B2 (en) 2003-03-20
IL128051A0 (en) 1999-11-30
PE20000169A1 (es) 2000-03-10
TW518224B (en) 2003-01-21
EA003247B1 (ru) 2003-02-27
GT199900004A (es) 2000-07-08

Similar Documents

Publication Publication Date Title
DZ2712A1 (fr) Composition de mésylate de trovafloxacine et procédé pour sa préparation.
DZ2826A1 (fr) Formulaons intranasales de mésylate de sildénafil et procédé pour leur préparation.
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2465A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2923A1 (fr) Formulations pharmaceutiques d'inhibiteurs de pde-5 de gmpc à libération contrôlée, et procédé pour leur préparation.
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2394A1 (fr) Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2114A1 (fr) Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.
DZ2440A1 (fr) Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant.
DZ2217A1 (fr) Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2751A1 (fr) Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2498A1 (fr) Dérivés de quinoléine nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2912A1 (fr) Procédé pour la préparation de pyrazolo Ä4,3-DÜpyrimidine-7-ones, et intermédiaires pour ce procédé.
DZ1946A1 (fr) Procédé pour la préparation de supports.